Civitas Therapeutics announced positive results for CVT-301, inhaled levodopa for the treatment of Parkinson’s at the AAN annual meeting last week. CVT-301 is in a Phase 2 clinical trial and it was demonstrated that it is safe and well tolerated by Parkinson’s patients. Inhaled levodopa is being developed to provide Parkinson’s patients with relief from debilitating motor fluctuations, known as Off episodes. We will continue to update the Parkinson’s community about future developments as this enters Phase 3 trials.
No comments:
Post a Comment